Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Medical Marijuana, Inc. Reports $7.8 Million in Net Revenue in 2022 Second Quarter Financial and Operational Results – Medical Marijuana, Inc.

SAN DIEGO, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United

May 3, 2023

Exclusive: Nocion raises $62M for different approach to chronic cough than Merck, GSK

In the middle of 2023, Richard Batycky told a couple of his fellow executives at Nocion Therapeutics to consider looking for roles elsewhere. He wasn’t

March 5, 2024

Amphastar Announces Additional $50 Million Increase to its Share Buyback Program – Biotech Investments

Rancho Cucamonga, 06/04/2024 / 03:00, PST/PDT – EQS Newswire – Amphastar Pharmaceuticals, Inc. RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals,

June 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.